These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7207885)

  • 1. Chelation therapy for iron overload.
    Nutr Rev; 1980 May; 38(5):185-7. PubMed ID: 7207885
    [No Abstract]   [Full Text] [Related]  

  • 2. Iron metabolism and chelation therapy in hemosiderosis.
    Graziano JH
    Curr Top Hematol; 1978; 1():127-50. PubMed ID: 400529
    [No Abstract]   [Full Text] [Related]  

  • 3. [Further experiences with iron-chelating therapy (desferrioxamine and ascorbic acid) in siderochromatosis and Cooley's disease].
    Cartei G; Cazzavillan M; Chisesi T; Battista R; Barbui T; Dini E
    Minerva Med; 1978 Mar; 69(13):811-21. PubMed ID: 643223
    [No Abstract]   [Full Text] [Related]  

  • 4. [Guidelines for diagnosis and treatment of secondary iron overload in patients with congenital anemia].
    Cario H; Grosse R; Janssen G; Jarisch A; Meerpohl J; Strauss G;
    Klin Padiatr; 2010 Nov; 222(6):399-406. PubMed ID: 20862634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biologically active hydroxamic acids--iron complexons].
    Kol'tsova GN; Mel'nikovskaia NN; Likhodzievskiĭ KG; Rozenberg GIa
    Gematol Transfuziol; 1984 Sep; 29(9):56-9. PubMed ID: 6394425
    [No Abstract]   [Full Text] [Related]  

  • 6. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ; Grady RW
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron chelation in acute iron poisoning and chronic hypersiderosis.
    Walsh JR; Gillick JB
    Clin Pediatr (Phila); 1965 Nov; 4(11):633-8. PubMed ID: 5844429
    [No Abstract]   [Full Text] [Related]  

  • 8. Iron chelation.
    Chandy M
    J Assoc Physicians India; 1991 Sep; 39(9):665-6. PubMed ID: 1814896
    [No Abstract]   [Full Text] [Related]  

  • 9. Chronic iron overload: new chelators and new strategies.
    Fairbanks VF
    J Lab Clin Med; 1978 Aug; 92(2):141-3. PubMed ID: 681806
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of desferrioxamine B and 2-(beta-aminoethoxy)cyclohexylaminetetraacetate in experimental hemochromatosis in rats and in primary hemochromatosis of man].
    Bohne F; Lessmann J
    Arzneimittelforschung; 1969 Jun; 19(6):944-7. PubMed ID: 5820039
    [No Abstract]   [Full Text] [Related]  

  • 11. [The treatment of post-transfusional hemochromatosis with chelating agents].
    Delvaux D; Andrien JM; Fillet G
    Rev Med Liege; 1981 Jun; 36(11):477-80. PubMed ID: 6789438
    [No Abstract]   [Full Text] [Related]  

  • 12. [Use of desferal in treatment of sideroses of different origin. (Literature review)].
    Turbina NS
    Probl Gematol Pereliv Krovi; 1968 Jul; 13(7):47-52. PubMed ID: 4898933
    [No Abstract]   [Full Text] [Related]  

  • 13. The treatment of hemosiderosis in thalassaemia major with desferrioxamine-B.
    Kirimlidis S; Philippidis P; Drossos C; Economidis J
    Helv Paediatr Acta; 1966 Sep; 21(4):343-50. PubMed ID: 5997620
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical usefulness of iron chelating agents.
    Waxman HS; Brown EB
    Prog Hematol; 1969; 6():338-73. PubMed ID: 4976246
    [No Abstract]   [Full Text] [Related]  

  • 15. [Specific treatment of excessive iron deposition in the tissues].
    Plachecka-Gutowska M; Mikolajew M
    Pol Arch Med Wewn; 1965; 35(1):111-7. PubMed ID: 5900073
    [No Abstract]   [Full Text] [Related]  

  • 16. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption.
    Kontoghiorghes GJ; Spyrou A; Kolnagou A
    Hemoglobin; 2010 Jun; 34(3):251-64. PubMed ID: 20524815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desferrioxamine-chelatable iron (DCI), a component of serum non-transferrin-bound iron (NTBI) used for assessing iron chelation therapy.
    Breuer W; Ermers MJ; Pootrakul P; Abramov A; Hershko C; Cabantchik ZI
    Transfus Sci; 2000 Dec; 23(3):241-2. PubMed ID: 11099901
    [No Abstract]   [Full Text] [Related]  

  • 18. [Myocardiopathy caused by iron deposition. Treatment with chelating agents].
    Rodríguez Reguero JJ; Iglesias Cubero G; Espolita Santos A; López de la Iglesia JM; Enríquez Martín J; Tomás Mauri J; López-Negrete L
    Rev Esp Cardiol; 1985; 38(5):356-7. PubMed ID: 4081244
    [No Abstract]   [Full Text] [Related]  

  • 19. Iron overload: pathogenesis and treatment with chelating agents.
    Huebers H
    Blut; 1983 Aug; 47(2):61-7. PubMed ID: 6871476
    [No Abstract]   [Full Text] [Related]  

  • 20. [Therapeutic results in the treatment of primary and secondary hemochromatoses with Desferal].
    Wöhler F
    Blut; 1967 Apr; 15(1):33-42. PubMed ID: 6025965
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.